FOLLICULAR LYMPHOMA GRADE 3B

This phase 2 trial is testing a combination of three drugs—tafasitamab, lenalidomide, and rituximab—in people aged 80 and older with untreated diffuse large B-cell lymphoma (DLBCL). The goal is to see if this gentler, chemotherapy-free regimen can shrink or eliminate tumors after…

This phase 3 trial compares a new immunotherapy called epcoritamab (given as a shot under the skin) to standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 483 participants will be randomly assigned to re…

This early-stage study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses specially engineered immune cells from a healthy donor to attack cancer cells. T…

This study tests a new drug called epcoritamab (given as a shot under the skin) against standard chemotherapy for people with diffuse large B-cell lymphoma that has come back or stopped responding to treatment. About 72 participants in China will be randomly assigned to get eithe…

This study was designed to test a combination of two drugs—golcadomide and nivolumab—in people with non-Hodgkin lymphoma whose cancer did not respond or came back after CAR-T cell therapy. The goal was to find a safe dose and see if the combo could shrink tumors. However, the tri…

This study aimed to see if combining three drugs—epcoritamab, lenalidomide, and tafasitamab—could safely treat diffuse large B-cell lymphoma that had come back or stopped responding to treatment. It was designed for adults with certain types of B-cell lymphoma. However, the trial…

This phase 2 trial is testing a personalized cell therapy called axi-cel for people with aggressive B-cell lymphoma that has come back or not responded to treatment, and who cannot undergo a stem cell transplant. The therapy uses the patient's own immune cells, which are modified…

This study tests whether adding an experimental drug called E7777 before standard CAR-T therapy can help people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 30 participants will receive E7777 followed by chemotherapy and a CAR-T produc…

This early-phase trial is testing whether adding the immunotherapy drug mosunetuzumab to standard chemotherapy can safely treat aggressive B-cell lymphoma that has come back or not responded to treatment. About 24 adults will receive either DHAX or ICE chemotherapy plus mosunetuz…

This early-phase study tests SC291, a CAR T-cell therapy made from donor cells, in 16 adults with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal is to check safety and see if the treatment can shrink tumors. Because it uses donor cell…